Aprea Therapeutics Inc (APRE)

$0.67 -0.08 (-10.32%)
Market Cap 5.57M
Revenue (ttm) 1.50M
Net Income (ttm) -12.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -864.00%
Debt to Equity Ratio 0.00
Volume 1,079,100
Avg Vol 2,443,040
Day's Range N/A - N/A
Shares Out 6.99M
Stochastic %K 13%
Beta 1.44
Analysts Sell
Price Target $4.50

Company Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid...

Industry: Biotechnology
Sector: Healthcare
Phone: 215 948 4119
Website: aprea.com
Address:
3805 Old Easton Road, Doylestown, United States
blank0o
blank0o Feb. 4 at 3:20 AM
$APRE
0 · Reply
_Papichulo_69
_Papichulo_69 Feb. 4 at 3:11 AM
$APRE EMA looks terrible all around. Get out fo this before it dumps again
0 · Reply
_Papichulo_69
_Papichulo_69 Feb. 4 at 12:24 AM
$APRE $.15
0 · Reply
KhokPiSDP
KhokPiSDP Feb. 3 at 8:15 PM
$APRE stupid move but the bottom is .66. More up potential.
0 · Reply
Bhaddar1
Bhaddar1 Feb. 3 at 4:46 PM
$APRE buy and hold baby xx
0 · Reply
_Papichulo_69
_Papichulo_69 Feb. 3 at 4:07 PM
$APRE delisting soon
1 · Reply
KhokPiSDP
KhokPiSDP Feb. 3 at 3:56 PM
$APRE 0.30 EOD to enter
0 · Reply
KhokPiSDP
KhokPiSDP Feb. 3 at 3:49 PM
$APRE Please 0.35 now
0 · Reply
Victory777777
Victory777777 Feb. 3 at 3:47 PM
$VIVS Push over $5 we will tending here then fly $APRE $BURU $FAT $SAFX $VIVS
0 · Reply
DaBullRunner
DaBullRunner Feb. 3 at 1:43 PM
$GXAI you ignored me here in the low $1’s👇 Now you are missing out on BIG gains 💰💰💰 🚨SPRC🚨quietly adding here See you all at $1+ easily $HCAI $APRE $RPGL $ELPW stay strong bulls ✊
0 · Reply
Latest News on APRE
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

Jan 29, 2026, 8:27 AM EST - 5 days ago

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 29, 2026, 8:25 AM EST - 5 days ago

Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

Dec 18, 2025, 8:30 AM EST - 6 weeks ago

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2025, 8:30 AM EST - 2 months ago

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

Nov 12, 2025, 8:30 AM EST - 2 months ago

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

Oct 24, 2025, 8:30 AM EDT - 3 months ago

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

Oct 15, 2025, 8:00 AM EDT - 3 months ago

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

Aug 28, 2025, 8:30 AM EDT - 5 months ago

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Aug 12, 2025, 8:00 AM EDT - 6 months ago

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

Jun 25, 2025, 9:00 AM EDT - 7 months ago

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

May 14, 2025, 8:00 AM EDT - 9 months ago

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Mar 31, 2025, 8:30 AM EDT - 11 months ago

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 25, 2025, 8:30 AM EDT - 11 months ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Mar 11, 2025, 8:30 AM EDT - 11 months ago

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Feb 5, 2025, 8:00 AM EST - 1 year ago

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Dec 11, 2024, 8:30 AM EST - 1 year ago

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Oct 9, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 9, 2024, 5:15 PM EDT - 1 year ago

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 9, 2024, 4:05 PM EDT - 1 year ago

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

May 28, 2024, 8:45 AM EDT - 1 year ago

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

May 14, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

May 13, 2024, 4:01 PM EDT - 1 year ago

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

May 2, 2024, 9:15 AM EDT - 1 year ago

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Apr 10, 2024, 12:00 PM EDT - 1 year ago

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 26, 2024, 7:45 AM EDT - 2 years ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Mar 14, 2024, 7:48 AM EDT - 2 years ago

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Mar 11, 2024, 8:30 AM EDT - 2 years ago

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Mar 11, 2024, 8:29 AM EDT - 2 years ago

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:45 PM EST - 2 years ago

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Feb 6, 2024, 8:01 AM EST - 2 years ago

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Jan 30, 2024, 8:00 AM EST - 2 years ago

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Nov 9, 2023, 4:05 PM EST - 2 years ago

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

Oct 16, 2023, 8:30 AM EDT - 2 years ago

Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 4:05 PM EDT - 2 years ago

Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

Aug 24, 2023, 7:30 AM EDT - 2 years ago

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

Aug 10, 2023, 7:30 AM EDT - 2 years ago

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference

Aprea Therapeutics to Present at BIO International Convention

May 30, 2023, 8:30 AM EDT - 2 years ago

Aprea Therapeutics to Present at BIO International Convention

Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

May 15, 2023, 4:05 PM EDT - 2 years ago

Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors

May 8, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors

blank0o
blank0o Feb. 4 at 3:20 AM
$APRE
0 · Reply
_Papichulo_69
_Papichulo_69 Feb. 4 at 3:11 AM
$APRE EMA looks terrible all around. Get out fo this before it dumps again
0 · Reply
_Papichulo_69
_Papichulo_69 Feb. 4 at 12:24 AM
$APRE $.15
0 · Reply
KhokPiSDP
KhokPiSDP Feb. 3 at 8:15 PM
$APRE stupid move but the bottom is .66. More up potential.
0 · Reply
Bhaddar1
Bhaddar1 Feb. 3 at 4:46 PM
$APRE buy and hold baby xx
0 · Reply
_Papichulo_69
_Papichulo_69 Feb. 3 at 4:07 PM
$APRE delisting soon
1 · Reply
KhokPiSDP
KhokPiSDP Feb. 3 at 3:56 PM
$APRE 0.30 EOD to enter
0 · Reply
KhokPiSDP
KhokPiSDP Feb. 3 at 3:49 PM
$APRE Please 0.35 now
0 · Reply
Victory777777
Victory777777 Feb. 3 at 3:47 PM
$VIVS Push over $5 we will tending here then fly $APRE $BURU $FAT $SAFX $VIVS
0 · Reply
DaBullRunner
DaBullRunner Feb. 3 at 1:43 PM
$GXAI you ignored me here in the low $1’s👇 Now you are missing out on BIG gains 💰💰💰 🚨SPRC🚨quietly adding here See you all at $1+ easily $HCAI $APRE $RPGL $ELPW stay strong bulls ✊
0 · Reply
TezBunny
TezBunny Feb. 3 at 12:45 PM
$APRE let’s cut this sucker down
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 3 at 12:30 AM
$APRE that financing was TOXIC 100% warrant coverage and they raise 5.5MM i really liked this name 5 yrs ago its a straight up MUTT WITH FLEAS now
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Feb. 2 at 11:10 PM
$APRE CEO purchased 28,100 shares at $0.89 for a total of $25,009. Gilad Oren now owns 375,520 shares. https://ceo-buys.com
0 · Reply
KhokPiSDP
KhokPiSDP Feb. 2 at 9:24 PM
$APRE late price update here. It already .75😜
0 · Reply
Dickman777
Dickman777 Feb. 2 at 7:45 PM
$FUSE loaded and ready $APRE buying all the dips… I’m patient $GCTS buying buying buying Have a plan folks
0 · Reply
DaBullRunner
DaBullRunner Feb. 2 at 6:31 PM
🚨GCTS🚨can’t wait until I show you a screenshot of this at a MUCH higher price like I did with ASTS👇🏆 $ELPW $APRE $XTKG $RPGL keep rocking ✊
0 · Reply
KhokPiSDP
KhokPiSDP Feb. 2 at 5:52 PM
$APRE
0 · Reply
Stonkman88
Stonkman88 Feb. 2 at 5:01 PM
$APRE $ELPW $MRNO $PBM $ROMA or you just follow the fat cat for freee!!🐈
0 · Reply
DaBullRunner
DaBullRunner Feb. 2 at 4:59 PM
$MRNO along with $ELPW will fully fund my 🚨GCTS🚨loads GCTS will be my BIGGEST PAY DAY of the year Remember this post $ROMA $APRE $PBM what a day
0 · Reply
GABBYGIRL
GABBYGIRL Feb. 2 at 4:24 PM
$APRE bk to 1.50
0 · Reply
easy123squeezy
easy123squeezy Feb. 2 at 4:18 PM
$APRE strong trend. Should test 1$
0 · Reply
Dickman777
Dickman777 Feb. 2 at 4:11 PM
$APRE we’re going back to dollar land $FUSE hanging around still volume, waiting for another break of 3.18
0 · Reply